A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
21 April, 2025
Trial data-sharing made easier with HeSANDA initiative
Latest News: 21 April 2025 TROG Cancer Research is
16 April, 2025
Mark Hughes Foundation grant for innovative SMART trial into brain metastases
LATEST NEWS: 15 April 2025 An innovative trial aimed
